BridgeBio Pharma, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving BridgeBio Pharma, Inc. now
Current reporting with the operating signal separated from the noise.
BridgeBio Pharma, Inc.: BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
The story matters when it changes BridgeBio Pharma, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
The story matters when it changes BridgeBio Pharma, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.BridgeBio Pharma, Inc. to Report First Quarter Financial Results and Program Updates on April 29, 2025
The story matters when it changes BridgeBio Pharma, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest BBIO filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
BridgeBio Pharma, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →